BioSpace News Archive

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.

AC Immune SA announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal March 5-9, 2024.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET.

argenx announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET to discuss its full year 2023 financial results and provide a fourth quarter business update.

Indivior PLC announced its financial results for the period ending December 31, 2023.

IRLAB Therapeutics AB announced that the company’s recent End-of-Phase 2 meeting with the US Food and Drug administration, FDA, was held in a constructive and engaging spirit.

Greenwich LifeSciences, Inc. provided the following update on the expansion of the clinical trial into Europe.

MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.